Module 3: Stay the Course – Toxicity Management, Adherence, and Continuity
Webcast
0.5 Contact Hours OVERVIEW
Module 3: Stay the Course – Toxicity Management, Adherence, and Continuity is organized by i3 Health.
Statement of Need:
As HER2-targeted therapies for non–small cell lung cancer (NSCLC) enter clinical practice, optimal management of their toxicities is increasingly crucial (Uy et al, 2022). Each class of medications is associated with a unique toxicity profile, including a risk of interstitial lung disease with antibody-drug conjugates (ADCs) and gastrointestinal and cutaneous side effects with tyrosine kinase inhibitors (TKIs) (Swain et al, 2022; Liu et al, 2024; Melosky et al, 2025). Oncology nurses play a critical role in monitoring for adverse events, educating patients on what to expect with their therapies and when to notify the care team, and promoting adherence to ensure optimal treatment outcomes (Belcher, 2022). Module 3 of this Clinical Insights Microlearning Series will explore nursing strategies for toxicity management and adherence optimization in HER2-mutant NSCLC. It will feature insights from Victoria Sherry, DNP, ANP-BC, AOCNP®, Oncology Nurse Practitioner for Thoracic Malignancies at Penn Medicine Abramson Cancer Center and Advanced Senior Lecturer at the University of Pennsylvania School of Nursing, with oncology perspectives from Zofia Piotrowska, MD, MHS, and pathology perspectives from Soo-Ryum (Stewart) Yang, MD.
Learning Objectives:
Upon completion of this activity, participants should be able to:
- Apply evidence-based nursing management of toxicities related to HER2-directed tyrosine kinase inhibitors (TKIs) and antibody-drug conjugates (ADCs)
ACCREDITATION & CREDITS
Nursing Continuing Professional Development
A maximum of 0.5 ANCC contact hours may be earned by learners who successfully complete this nursing continuing professional development activity. This activity has been designated for 0.5 contact hours of pharmacology credit for Advanced Practice Registered Nurses.
Provider approved by the California Board of Registered Nursing, Provider Number 15824, for 0.5 ANCC contact hours.
ONCC RECERTIFICATION:
The program content has been reviewed by the Oncology Nursing Certification Corporation (ONCC) and is acceptable for recertification points.
ONCC review is only for designating content to be used for recertification points and is not for NCPD accreditation. NCPD programs must be formally approved for contact hours by an acceptable accreditor/approver of NCPD to be used for recertification by ONCC. If the NCPD provider fails to obtain formal approval to award contact hours by an acceptable accrediting/approval body, no information related to ONCC recertification may be used in relation to the program.
- OCN®, CPHON®, CBCN®, AOCNP®, AOCNS®, TCTCN®, ROCN®, and BMTCN® renewal candidates may apply 0.5 ILNA points toward:
- Oncology Nursing Practice (OCN®, CPHON®, AOCNP®)
- Symptom Management, Palliative Care, Supportive Care (OCN®, CPHON®, AOCNP®)
- Treatment (AOCNP®, CBCN®, CPHON®, OCN®, ROCN®)
Please note that some of the course content applies to multiple content areas. The numerical value above indicates the maximum amount of points that can be claimed in each domain. The total amount of ILNA points claimed may not exceed the total amount of NCPD awarded from this course.
SPECIALITIES
Oncology
Download eMedEvents Mobile App
Track your CE certificates and CME requirements anytime, anywhere.
Quick Links